Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion

Yosef Landman; Maya Ilouze; Simon Wein; Victoria Neiman; Rinat Yerushalmi; Maxim Yakimov; Nora Ku; Alexa B. Schrock; Siraj Ali; Nir Peled

doi:10.1016/j.clbc.2017.11.017

Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion

Yosef Landman, Maya Ilouze, Simon Wein, Victoria Neiman, Rinat Yerushalmi, Maxim Yakimov, Nora Ku, Alexa B. Schrock, Siraj Ali, Nir Peled^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Original language	English
Pages (from-to)	e267-e270
Journal	Clinical Breast Cancer
Volume	18
Issue number	3
DOIs	https://doi.org/10.1016/j.clbc.2017.11.017
State	Published - Jun 2018
Externally published	Yes

Keywords

NGS
NTRK3
SBC
TNBC
Targeted therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clbc.2017.11.017

Cite this

Landman, Y., Ilouze, M., Wein, S., Neiman, V., Yerushalmi, R., Yakimov, M., Ku, N., Schrock, A. B., Ali, S., & Peled, N. (2018). Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion. Clinical Breast Cancer, 18(3), e267-e270. https://doi.org/10.1016/j.clbc.2017.11.017

@article{3e957a1b7ea94dd4bfe1191a46a61ccd,

title = "Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion",

keywords = "NGS, NTRK3, SBC, TNBC, Targeted therapy",

author = "Yosef Landman and Maya Ilouze and Simon Wein and Victoria Neiman and Rinat Yerushalmi and Maxim Yakimov and Nora Ku and Schrock, {Alexa B.} and Siraj Ali and Nir Peled",

year = "2018",

month = jun,

doi = "10.1016/j.clbc.2017.11.017",

language = "אנגלית",

volume = "18",

pages = "e267--e270",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

publisher = "Elsevier Inc.",

number = "3",

}

Landman, Y, Ilouze, M, Wein, S, Neiman, V, Yerushalmi, R, Yakimov, M, Ku, N, Schrock, AB, Ali, S & Peled, N 2018, 'Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion', Clinical Breast Cancer, vol. 18, no. 3, pp. e267-e270. https://doi.org/10.1016/j.clbc.2017.11.017

TY - JOUR

T1 - Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion

AU - Landman, Yosef

AU - Ilouze, Maya

AU - Wein, Simon

AU - Neiman, Victoria

AU - Yerushalmi, Rinat

AU - Yakimov, Maxim

AU - Ku, Nora

AU - Schrock, Alexa B.

AU - Ali, Siraj

AU - Peled, Nir

PY - 2018/6

Y1 - 2018/6

KW - NGS

KW - NTRK3

KW - SBC

KW - TNBC

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85037671711&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2017.11.017

DO - 10.1016/j.clbc.2017.11.017

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 29233640

AN - SCOPUS:85037671711

SN - 1526-8209

VL - 18

SP - e267-e270

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

IS - 3

ER -

Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion

Keywords

UN SDGs

Access to Document

Other files and links

Cite this